GLP-1 Receptor Agonists: A Game-Changer for Kidney Disease Patients
Summary
- GLP-1s Go Beyond Blood Sugar - Originally developed for diabetes (think Ozempic, Wegovy, Trulicity), GLP-1 receptor agonists also reduce protein in the urine, slow the decline in kidney function, and reduce the risk of kidney failure, especially in individuals with type 2 diabetes or insulin resistance.
- Protective Effects with a Functional Lens - These medications may reduce inflammation in the kidneys, lower blood pressure, support weight loss, and directly protect kidney cells. They align with functional medicine goals by targeting root causes, not just symptoms.
- Real-World Impact - Dr. Bismah shares the case of a patient with Stage 3 chronic kidney disease (CKD) who experienced significant improvements in HbA1c, proteinuria, kidney function, weight, and blood pressure after starting a GLP-1 receptor agonist, with minimal side effects and no dose adjustments required for kidney function.
